Danny Bar-Zohar

No­var­tis vet Dan­ny Bar-Zo­har leaps back in­to R&D, tak­ing over the de­vel­op­ment team at Mer­ck KGaA as Lu­ciano Ros­set­ti steps out

Af­ter a brief stint as a biotech in­vestor at Syn­cona, No­var­tis vet Dan­ny Bar-Zo­har is back in R&D, and he’s tak­ing the lead po­si­tion at Mer­ck KGaA’s drug di­vi­sion.

Bar-Zo­har had led late-stage clin­i­cal de­vel­op­ment across a va­ri­ety of ar­eas — neu­ro­science, im­munol­o­gy, on­col­o­gy and oph­thal­mol­o­gy, among oth­ers — be­fore join­ing the mi­gra­tion of tal­ent out of the Basel-based multi­na­tion­al. He had been at No­var­tis for 7 years, which fol­lowed an ear­li­er chap­ter in re­search at Te­va.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.